PPT-2020 Year in Review: Breast Cancer

Lisa A Carey MD ScM University of North Carolina Lineberger Comprehensive Cancer Center     HER2Positive Disease Courtesy of Lisa Carey MD ExteNET Background Final efficacy analysis of a trial that was the basis for approval of neratinib for extended adjuvant therapy in HER2positive . nbcamorg reast cancer is the second most common kind of cancer in women About 1 in 8 women born today in the United States will get breast cancer at some point The good news is that many women can survive breast cancer if its found and treated earl What’s New to Know?. The Issue of Breast Density. Catherine Babcook MD. Partner, Mountain Medical Physician Specialists. Medical Director of Breast Imaging McKay Dee Hospital Center. Disclosure. This presentation has no commercial content, promotes no commercial vendor and is not supported financially by any commercial vendor. I receive no financial remuneration from any commercial vendor related to this presentation.. DR. A. AKHATOR FWACS, FICS. SENIOR LECTURER DELSU . CONSULTANT SURGEON DELSUTH. PRE-TEST. Breast cancer is the most common cancer in women in Nigeria . Breast cancer is the most common cause of cancer related deaths. Diana Sarfati. Director, Cancer Control and Screening Research Group. Breast cancer. Most common cancer for women in NZ . 600 women die each year from breast cancer. Trends . in age standardized I. ncidence . Changing Philosophies in Educating Women and Teens . Courtney Benedict CNM MSN. Disclosures. Merck Nexplanon trainer . Session Objectives. Explain the rationale for initiation and frequency of clinical breast exams to clients. SWAG Site Specific Group. Maxine Taylor. Senior Research Delivery Manager - Cancer. Friday 1. st. July . 2016. Clinical Research Network. West of England. South West Research Networks & SWAG. West of England. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Breast Cancer Overview. The . most common breast cancer starts in cells of the . ducts.. Breast . cancer is the second most common cancer for women in the U.S. . Reference . 2. Breast Cancer Statistics. Friday 27. th. January 2017. Research Report. Clinical Research Network. West of England. Clinical Research Network & Cancer Services. West . ofEngland. SWAG - Somerset . Wiltsire. Avon & Gloucestershire. Kristin . DePrince. Mattie, M.S.. Licensed / Certified Genetic Counselor. William G. Rohrer Cancer Genetics Program. Objectives. Describe . current approaches to genetic testing for hereditary cancer syndromes. Dr. Ruth . Heisey. Family Physician/GP Oncologist. Women’s College Hospital/Princess Margaret . Cancer Centre. Clinician Investigator/Associate Professor. University of Toronto. Sandy Fawcett . RN(EC) NP-Adult. Generosa. . Grana. , MD. Professor, Cooper Medical School of Rowan University. Director, MD Anderson Cancer Center at Cooper. Overview. Factors that affect breast cancer risk. Tools to assess risk. Role of genetics in this process. Steven J. Katz MD MPH. Professor of Medicine and Health Management and Policy. University of Michigan . Allison Kurian MD M Sc.. Professor of Medicine and Medical Genetics . Stanford University . Guidelines 2019. March 2019. Preview/Introduction. The Risk of Breast Cancer to Women. Does Mammography Save Lives?. When to Start and How Often Should Women Screen?. Risks Versus Benefits of Mammography. Breast Cancer: The Impact on Women.